Drug-induced eosinophilic pneumonia in a patient with Crohn's disease: diagnosis and treatment using fraction of exhaled nitric oxide
Intestinal Research
;
: 529-534, 2017.
Article
Dans Anglais
| WPRIM
| ID: wpr-220093
ABSTRACT
Oral 5-aminosalicylic acid agents (mesalazine and sulfasalazine) and azathioprine are the mainstays of treatment for inflammatory bowel disease. Reports of pulmonary toxicity induced by oral 5-aminosalicylic acid agents or azathioprine in patients with inflammatory bowel disease are very rare; to date, only 38 cases have been reported worldwide. We, herein, report a case involving a 26-year-old man who was diagnosed with eosinophilic pneumonia after using mesalazine and azathioprine for the treatment of Crohn's disease and recovered after treatment. We also found that the fraction of exhaled nitric oxide level was elevated in this patient. After treatment, the fraction of exhaled nitric oxide level decreased and the symptoms improved. The present case shows that fraction of exhaled nitric oxide is related to the disease activity and treatment effectiveness of druginduced eosinophilic pneumonia.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Poumon éosinophile
/
Azathioprine
/
Maladies inflammatoires intestinales
/
Maladie de Crohn
/
Résultat thérapeutique
/
Mésalazine
/
Diagnostic
/
Granulocytes éosinophiles
/
Monoxyde d'azote
Type d'étude:
Etude diagnostique
Limites du sujet:
Adulte
/
Humains
langue:
Anglais
Texte intégral:
Intestinal Research
Année:
2017
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS